Does Vermont Medicaid Cover Wegovy or Zepbound? Heart, MASH and Sleep Apnea Only

Not for weight loss. As of November 2026, Vermont Medicaid excludes drugs used for weight loss from its pharmacy program, Wegovy and Zepbound included.^[1] It does cover Wegovy injection as a preferred drug to cut heart risk or treat MASH, and Zepbound for sleep apnea, in each case only for people who do not have diabetes.^[1]

Will Vermont Medicaid pay for Wegovy or Zepbound to lose weight?

No. The first page of Vermont’s drug list groups weight-loss drugs with fertility, cosmetic and hair growth drugs as categories its pharmacy program does not cover.^[1] The semaglutide request form opens by asking whether the drug is for weight loss only, and reminds prescribers that the state does not allow coverage for weight loss products.^[2] Under federal law, a state may make that choice.^[6] Our explainer on how state Medicaid programs treat Ozempic and Wegovy covers the background.

When does Vermont Medicaid cover a GLP-1?

The diabetes line runs through every non-diabetes route. The Wegovy criteria state that the patient must not have diabetes, and the Zepbound criteria rule out type 2 diabetes.^[1] The request form asks for a current A1C and whether the patient is diabetic, and if so which drugs have been tried.^[2] People with diabetes are meant to use the diabetes GLP-1s instead.^[1]

What does Vermont require for Wegovy for heart disease?

Vermont places Wegovy injection in a class it calls cardiometabolic health agents, in the preferred column, with a limit of four pens every 28 days.^[1] For the heart route the patient needs a BMI over 27 and a history of stroke, heart attack or symptomatic peripheral artery disease, plus counseling on diet and activity.^[1] The request form adds one more question: whether the patient is also taking a cholesterol-lowering drug.^[2] That matches the Wegovy label, which covers adults with established heart disease who are overweight or have obesity.^[7]

Renewal sets no weight target. After the first six months, the prescriber confirms the diet and activity plan continues and attests to clinical benefit, meaning lower heart risk.^[1] Wegovy tablets are approved only after the injection has failed.^[1]

Does Vermont Medicaid cover Wegovy for MASH?

Yes, for the injection only. The patient needs MASH with F2 or F3 fibrosis, shown by a biopsy or by two noninvasive tests, one blood-based and one imaging-based, and must not have decompensated cirrhosis.^[1] A gastroenterologist, hepatologist or endocrinologist must prescribe or consult.^[1] Renewal after six months asks for a positive response and no progression to F4 cirrhosis.^[1]

Vermont also sets an order between the two MASH drugs. Rezdiffra (resmetirom), the other MASH drug in the class, is non-preferred and is approved only once Wegovy has failed, caused side effects or an allergy, or cannot be used.^[1] The FDA approved Wegovy for MASH on an accelerated basis.^[7]

Does Vermont Medicaid cover Zepbound for sleep apnea?

Yes. Zepbound is the only drug in Vermont’s sleep apnea class and is preferred once criteria are met.^[1] The patient needs a sleep study with an AHI above 15, a BMI above 30 and weight counseling, and must not have type 2 diabetes, class IV heart failure, or a serious cardiac event such as a heart attack, stroke, unstable angina or heart failure admission in the past three months.^[1] Both cutoffs read “greater than,” so a result of exactly 15 or a BMI of exactly 30 would not qualify on the written text.^[1]

On CPAP, the bar is low: the patient must have been prescribed CPAP, not shown that it failed.^[1] The Zepbound label covers moderate to severe sleep apnea in adults with obesity and sets no CPAP condition.^[8] Renewal after six months needs weight loss of more than 5% from baseline or a kept initial 5% loss.^[1]

Does Vermont Medicaid cover Ozempic and Mounjaro for diabetes?

Yes. Exenatide, Mounjaro, the Ozempic pen, Rybelsus, Trulicity and Victoza are preferred once the one clinical criterion is met: a type 2 diabetes diagnosis.^[1] Vermont defines treatment failure as an A1C drop under 1% after 12 weeks at the highest tolerated dose, which matters when moving to a non-preferred drug.^[1] The Ozempic tablet, for example, needs failure of two preferred GLP-1s, one of them injectable Ozempic, or a clinical reason the patient cannot inject.^[1]

How do you get a request approved or appeal a denial in Vermont?

The prescriber fills in the state’s semaglutide or Zepbound request form and faxes it to Optum at 1-844-679-5366; the prescriber line is 1-844-679-5363, and Optum says fax requests get an answer within 24 hours.^[1][2][3] A denial for missing chart notes, fibrosis tests or an A1C is usually fixed by refiling with them. A request for weight loss alone has no route to argue.^[1]

A member who disagrees first files an internal appeal with Vermont Medicaid, which decides within 30 days, with up to 14 more days if needed.^[4] If that fails, the member has 120 days from the date on the internal appeal letter to ask the Human Services Board for a fair hearing, by phone at 802-828-2536, through the customer support line at 1-800-250-8427, online, by email, by letter or in person.^[4] Free help is available from Vermont Legal Aid’s Office of Health Care Advocate at 1-800-917-7787.^[4] Our guide to prior authorization and appeals covers what to send, and the Vermont state page gathers the same facts in brief.

What if Vermont Medicaid will not pay?

Copay cards from the makers do not apply: Lilly’s Zepbound card excludes anyone enrolled in a government-funded program such as Medicaid.^[9] In the cash prices we track, Novo Nordisk sells most Wegovy pen doses for $349 a month, and Lilly’s self-pay Zepbound costs $299 at the first dose, $399 at 5 mg and $449 at higher doses refilled on time.^[9][10] Our roundup of the lowest GLP-1 prices without insurance compares them.